Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Price & Overview
NASDAQ:CRBP • US21833P3010
Current stock price
10.3 USD
+0.42 (+4.25%)
At close:
10.2502 USD
-0.05 (-0.48%)
After Hours:
The current stock price of CRBP is 10.3 USD. Today CRBP is up by 4.25%. In the past month the price increased by 1.28%. In the past year, price increased by 32.22%.
CRBP Key Statistics
52-Week Range6.1 - 20.56
Current CRBP stock price positioned within its 52-week range.
1-Month Range9.5 - 11
Current CRBP stock price positioned within its 1-month range.
- Market Cap
- 182.722M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.98
- Dividend Yield
- N/A
CRBP Stock Performance
Today
+4.25%
1 Week
+2.39%
1 Month
+1.28%
3 Months
+24.55%
Longer-term
6 Months -15.23%
1 Year +32.22%
2 Years -75.93%
3 Years +8.76%
5 Years -84.18%
10 Years -89.47%
CRBP Stock Chart
CRBP Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CRBP. When comparing the yearly performance of all stocks, CRBP is one of the better performing stocks in the market, outperforming 82.39% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CRBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRBP. While CRBP has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CRBP Earnings
Next Earnings DateMay 4, 2026
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$1.25
Revenue Reported
EPS Surprise 22.24%
Revenue Surprise -100.00%
CRBP Forecast & Estimates
16 analysts have analysed CRBP and the average price target is 41.37 USD. This implies a price increase of 301.62% is expected in the next year compared to the current price of 10.3.
Analysts
Analysts86.25
Price Target41.37 (301.65%)
EPS Next Y21.71%
Revenue Next Year0%
CRBP Index Membership
CRBP is currently included in the following stock indexes tracked on ChartMill.
CRBP Financial Highlights
Over the last trailing twelve months CRBP reported a non-GAAP Earnings per Share(EPS) of -5.98. The EPS decreased by -63.39% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-78.54M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.69% | ||
| ROE | -53.24% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-60.26%
Sales Q2Q%N/A
EPS 1Y (TTM)-63.39%
Revenue 1Y (TTM)N/A
CRBP Ownership
Ownership
Inst Owners66.94%
Shares17.74M
Float16.02M
Ins Owners0.55%
Short Float %8.39%
Short Ratio5.91
CRBP Industry Overview
CRBP operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
CRBP Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRBP
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Company Info
IPO: 2014-10-24
CORBUS PHARMACEUTICALS HOLDI
500 River Ridge Drive
Norwood MASSACHUSETTS 02062 US
CEO: Yuval Cohen
Employees: 36
Phone: 16179630103
CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ
What does CORBUS PHARMACEUTICALS HOLDI do?
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Can you provide the latest stock price for CORBUS PHARMACEUTICALS HOLDI?
The current stock price of CRBP is 10.3 USD. The price increased by 4.25% in the last trading session.
Does CRBP stock pay dividends?
CRBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of CRBP stock?
CRBP has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CRBP stock?
CORBUS PHARMACEUTICALS HOLDI (CRBP) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP)?
CORBUS PHARMACEUTICALS HOLDI (CRBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.98).
What is the next earnings date for CRBP stock?
CORBUS PHARMACEUTICALS HOLDI (CRBP) will report earnings on 2026-05-04.